Alzheimer’s

MHRA Grants ADvantage Therapeutics Innovative Licensing and Access Pathway (ILAP) Designation for Novel Lead Product AD04™ for Phase 2b Trial in Alzheimer’s DiseaseMHRA Grants ADvantage Therapeutics Innovative Licensing and Access Pathway (ILAP) Designation for Novel Lead Product AD04™ for Phase 2b Trial in Alzheimer’s Disease

MHRA Grants ADvantage Therapeutics Innovative Licensing and Access Pathway (ILAP) Designation for Novel Lead Product AD04™ for Phase 2b Trial in Alzheimer’s Disease

ILAP Designation accelerates patient access and commercialization  MIAMI, APRIL 5, 2023 (GLOBE NEWSWIRE) – ADvantage Therapeutics, Inc. (“ADvantage” or “the…

2 years ago
MetAlert, Inc. Selects Pod Group’s ENO ONE eSIM Solution to Connect “SmartSole” Healthcare ApplicationMetAlert, Inc. Selects Pod Group’s ENO ONE eSIM Solution to Connect “SmartSole” Healthcare Application

MetAlert, Inc. Selects Pod Group’s ENO ONE eSIM Solution to Connect “SmartSole” Healthcare Application

Mission-Critical GPS SmartSole Allows Users to Track the Whereabouts of Loved Ones with Alzheimer’s and Autism  Cambridge, UK, October 26th…

2 years ago
Treating Alzheimer’s: Is It Really an Autoimmune Disease?Treating Alzheimer’s: Is It Really an Autoimmune Disease?

Treating Alzheimer’s: Is It Really an Autoimmune Disease?

Although Alzheimer’s is still listed as an incurable neurodegenerative disease, medical science has come a long way in terms of…

2 years ago